Cervical screening : ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)

Show full item record



Permalink

http://hdl.handle.net/10138/333779

Citation

Kyrgiou , M , Arbyn , M , Bergeron , C , Bosch , F X , Dillner , J , Jit , M , Kim , J , Poljak , M , Nieminen , P , Sasieni , P , Kesic , V , Cuzick , J & Gultekin , M 2020 , ' Cervical screening : ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC) ' , British Journal of Cancer , vol. 123 , no. 4 , pp. 510-517 . https://doi.org/10.1038/s41416-020-0920-9

Title: Cervical screening : ESGO-EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC)
Author: Kyrgiou, Maria; Arbyn, Marc; Bergeron, Christine; Bosch, F. Xavier; Dillner, Joakim; Jit, Mark; Kim, Jane; Poljak, Mario; Nieminen, Pekka; Sasieni, Peter; Kesic, Vesna; Cuzick, Jack; Gultekin, Murat
Other contributor: University of Helsinki, HUS Gynecology and Obstetrics



Date: 2020-08-18
Language: eng
Number of pages: 8
Belongs to series: British Journal of Cancer
ISSN: 0007-0920
DOI: https://doi.org/10.1038/s41416-020-0920-9
URI: http://hdl.handle.net/10138/333779
Abstract: This paper summarises the position of ESGO and EFC on cervical screening based on existing guidelines and opinions of a team of lead experts. HPV test is replacing cytology as this offers greater protection against cervical cancer and allows longer screening intervals. Only a dozen of HPV tests are considered as clinically validated for screening. The lower specificity of HPV test dictates the use of triage tests that can select women for colposcopy. Reflex cytology is currently the only well validated triage test; HPV genotyping and p16 immunostaining may be used in the future, although methylation assays and viral load also look promising. A summary of quality assurance benchmarks is provided, and the importance to audit the screening histories of women who developed cancer is noted as a key objective. HPV-based screening is more cost-effective than cytology or cotesting. HPV-based screening should continue in the post-vaccination era. Only a fraction of the female population is vaccinated, and this varies across countries. A major challenge will be to personalise screening frequency according to vaccination status. Still the most important factor for successful prevention by screening is high population coverage and organised screening. Screening with self-sampling to reach under-screened women is promising.
Subject: HIGH-RISK HPV
INTRAEPITHELIAL NEOPLASIA
COST-EFFECTIVENESS
CANCER PRECURSORS
QUALITY-ASSURANCE
CYTOLOGY
WOMEN
GUIDELINES
TESTS
PERFORMANCE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
s41416_020_0920_9.pdf 316.7Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record